Eloxx Pharmaceuticals IncOTC Pink - Limited Information:ELOX
- LAST PRICE0.9400
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.9500 / 0.9400
- Day Range
- 52 Week Range
- Volume8,256
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ELOX |
|---|---|---|
| 10:19 ET | 250 | 0.95 |
| 10:21 ET | 300 | 0.975 |
| 03:48 ET | 3499 | 0.98 |
| 03:52 ET | 3775 | 0.94 |
| 03:54 ET | 200 | 0.94 |
| 03:56 ET | 100 | 0.94 |
Apr 16, 2024
Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates, from 7:30AM ET on Tuesday Apr 16, 2024 by Dow Jones
7:30AM ET on Tuesday Apr 16, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Eloxx Pharmaceuticals Inc | 3.0M | -0.1x | --- |
Phio Pharmaceuticals Corp | 2.9M | -0.1x | --- |
Evolutionary Genomics Inc | 3.0M | -1.3x | --- |
Atreca Inc | 3.0M | 0.0x | --- |
Transcode Therapeutics Inc | 2.9M | 0.0x | --- |
Windtree Therapeutics Inc | 3.1M | 0.0x | --- |
Company Information
Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the science of ribosome modulation, leveraging both its TURBO- ZM chemistry technology platform and its library of aminoglycosides to develop oral small-molecule ribosome modulating agents (RMAs) and eukaryotic ribosome selective glycosides (ERSGs) for the treatment of rare and ultra-rare genetic diseases. Its lead investigational product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. The Company is also advancing ZKN-013 as an oral agent for the treatment of recessive dystrophic (RDEB)/ junctional epidermolysis bullosa (JEB) and familial adenomatous polyposis (FAP) patients with nonsense mutations. The Company also has preclinical programs focused on select rare diseases, including inherited diseases, cancer caused by nonsense mutations, kidney diseases, as well as rare ocular genetic disorders.
Contact Information
- Headquarters
- 480 ARSENAL WAY, SUITE 130WATERTOWN, MA, United States 02472
- Phone
- 781-577-5300
- Fax
- 302-636-5454
Executives
- President, Chief Executive Officer, Director
- Sumit Aggarwal
- Interim Chief Financial Officer
- Daniel Geffken
- Independent Director
- Lindsay Androski
- Independent Director
- Steven Rubin
- Independent Director
- Alan Walts
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.0M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 3.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.72 |
EPS | $-9.06 |
Book Value | $-4.92 |
P/E Ratio | -0.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
